drugset
drugset / Trial / NCT06711900

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06711900 ↗

Phase 3 Active not recruiting 432 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.

Timeline

Start
2024-10-30
Primary completion
2026-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule — Intravenous
Comparator Cisplatin Other / unclassified — Intravenous
Subject Pembrolizumab Monoclonal antibody — Intravenous
Comparator Pemetrexed Small molecule — Intravenous
Subject Sacituzumab Tirumotecan Other / unclassified — Intravenous

Indications

non-small cell lung carcinoma